353 related articles for article (PubMed ID: 35886862)
1. Type 2 Transglutaminase in Coeliac Disease: A Key Player in Pathogenesis, Diagnosis and Therapy.
Paolella G; Sposito S; Romanelli AM; Caputo I
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886862
[TBL] [Abstract][Full Text] [Related]
2. Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.
Martucciello S; Paolella G; Esposito C; Lepretti M; Caputo I
Cell Mol Life Sci; 2018 Nov; 75(22):4107-4124. PubMed ID: 30136165
[TBL] [Abstract][Full Text] [Related]
3. Transglutaminase 2 and Transglutaminase 2 Autoantibodies in Celiac Disease: a Review.
Rauhavirta T; Hietikko M; Salmi T; Lindfors K
Clin Rev Allergy Immunol; 2019 Aug; 57(1):23-38. PubMed ID: 27263022
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Detection of Isopeptides between Human Tissue Transglutaminase and Gluten Peptides.
Lexhaller B; Ludwig C; Scherf KA
Nutrients; 2019 Sep; 11(10):. PubMed ID: 31547042
[TBL] [Abstract][Full Text] [Related]
5. Gluten induces coeliac-like disease in sensitised mice involving IgA, CD71 and transglutaminase 2 interactions that are prevented by probiotics.
Papista C; Gerakopoulos V; Kourelis A; Sounidaki M; Kontana A; Berthelot L; Moura IC; Monteiro RC; Yiangou M
Lab Invest; 2012 Apr; 92(4):625-35. PubMed ID: 22330344
[TBL] [Abstract][Full Text] [Related]
6. Identification of Isopeptides Between Human Tissue Transglutaminase and Wheat, Rye, and Barley Gluten Peptides.
Lexhaller B; Ludwig C; Scherf KA
Sci Rep; 2020 May; 10(1):7426. PubMed ID: 32367038
[TBL] [Abstract][Full Text] [Related]
7. Celiac anti-type 2 transglutaminase antibodies induce differential effects in fibroblasts from celiac disease patients and from healthy subjects.
Paolella G; Lepretti M; Barone MV; Nanayakkara M; Di Zenzo M; Sblattero D; Auricchio S; Esposito C; Caputo I
Amino Acids; 2017 Mar; 49(3):541-550. PubMed ID: 27613408
[TBL] [Abstract][Full Text] [Related]
8. Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process.
Fleckenstein B; Molberg Ø; Qiao SW; Schmid DG; von der Mülbe F; Elgstøen K; Jung G; Sollid LM
J Biol Chem; 2002 Sep; 277(37):34109-16. PubMed ID: 12093810
[TBL] [Abstract][Full Text] [Related]
9. Injection of prototypic celiac anti-transglutaminase 2 antibodies in mice does not cause enteropathy.
Lindstad CB; du Pré MF; Stamnaes J; Sollid LM
PLoS One; 2022; 17(4):e0266543. PubMed ID: 35385534
[TBL] [Abstract][Full Text] [Related]
10. Igs as Substrates for Transglutaminase 2: Implications for Autoantibody Production in Celiac Disease.
Iversen R; Fleur du Pré M; Di Niro R; Sollid LM
J Immunol; 2015 Dec; 195(11):5159-68. PubMed ID: 26503953
[TBL] [Abstract][Full Text] [Related]
11. Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease.
Büchold C; Hils M; Gerlach U; Weber J; Pelzer C; Heil A; Aeschlimann D; Pasternack R
Cells; 2022 May; 11(10):. PubMed ID: 35626704
[TBL] [Abstract][Full Text] [Related]
12. Interplay between Type 2 Transglutaminase (TG2), Gliadin Peptide 31-43 and Anti-TG2 Antibodies in Celiac Disease.
Martucciello S; Sposito S; Esposito C; Paolella G; Caputo I
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32456177
[TBL] [Abstract][Full Text] [Related]
13. Management of celiac disease in daily clinical practice.
Elli L; Ferretti F; Orlando S; Vecchi M; Monguzzi E; Roncoroni L; Schuppan D
Eur J Intern Med; 2019 Mar; 61():15-24. PubMed ID: 30528262
[TBL] [Abstract][Full Text] [Related]
14. Transglutaminase 2-targeted autoantibodies in celiac disease: Pathogenetic players in addition to diagnostic tools?
Lindfors K; Mäki M; Kaukinen K
Autoimmun Rev; 2010 Sep; 9(11):744-9. PubMed ID: 20547248
[TBL] [Abstract][Full Text] [Related]
15. Substrates, inhibitors, and probes of mammalian transglutaminase 2.
Zhuang R; Khosla C
Anal Biochem; 2020 Feb; 591():113560. PubMed ID: 31874171
[TBL] [Abstract][Full Text] [Related]
16. Constitutive Differential Features of Type 2 Transglutaminase in Cells Derived from Celiac Patients and from Healthy Subjects.
Paolella G; Nanayakkara M; Sposito S; Lepretti M; Auricchio S; Esposito C; Barone MV; Martucciello S; Caputo I
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32059410
[TBL] [Abstract][Full Text] [Related]
17. Intestinal titres of anti-tissue transglutaminase 2 antibodies correlate positively with mucosal damage degree and inversely with gluten-free diet duration in coeliac disease.
Tosco A; Auricchio R; Aitoro R; Ponticelli D; Primario M; Miele E; Rotondi Aufiero V; Discepolo V; Greco L; Troncone R; Maglio M
Clin Exp Immunol; 2014 Sep; 177(3):611-7. PubMed ID: 24773630
[TBL] [Abstract][Full Text] [Related]
18. Intestinal anti-tissue transglutaminase antibodies in potential coeliac disease.
Tosco A; Aitoro R; Auricchio R; Ponticelli D; Miele E; Paparo F; Greco L; Troncone R; Maglio M
Clin Exp Immunol; 2013 Jan; 171(1):69-75. PubMed ID: 23199325
[TBL] [Abstract][Full Text] [Related]
19. Epitope-dependent Functional Effects of Celiac Disease Autoantibodies on Transglutaminase 2.
Hnida K; Stamnaes J; du Pré MF; Mysling S; Jørgensen TJ; Sollid LM; Iversen R
J Biol Chem; 2016 Dec; 291(49):25542-25552. PubMed ID: 27784785
[TBL] [Abstract][Full Text] [Related]
20. Transglutaminase 2 in celiac disease: minireview article.
Caputo I; D'Amato A; Troncone R; Auricchio S; Esposito C
Amino Acids; 2004 Jul; 26(4):381-6. PubMed ID: 15290344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
